{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:57:10Z","timestamp":1759694230229,"version":"3.37.3"},"reference-count":39,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","ajconline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.amjcard.2016.08.089","type":"journal-article","created":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T19:02:22Z","timestamp":1474052542000},"page":"1948-1953","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Benefits of Heart Rate Slowing With Ivabradine in Patients With Systolic Heart Failure and Coronary Artery Disease"],"prefix":"10.1016","volume":"118","author":[{"given":"Jeffrey S.","family":"Borer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prakash C.","family":"Deedwania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6942-4037","authenticated-orcid":false,"given":"Jae B.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2015","series-title":"Corlanor (Ivabradine). Full Prescribing Information","key":"10.1016\/j.amjcard.2016.08.089_bib1"},{"key":"10.1016\/j.amjcard.2016.08.089_bib2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1749-6632.2011.05960.x","article-title":"Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine","volume":"1222","author":"Canet","year":"2011","journal-title":"Ann N Y Acad Sci"},{"year":"2005","series-title":"Procoralan (Ivabradine). Summary of Product Characteristics","key":"10.1016\/j.amjcard.2016.08.089_bib3"},{"key":"10.1016\/j.amjcard.2016.08.089_bib4","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","volume":"33","author":"McMurray","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2016.08.089_bib5","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/eurheartj\/4.suppl_A.173","article-title":"Beta-blockers in dilated cardiomyopathies: they work","volume":"4 suppl A","author":"Waagstein","year":"1983","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2016.08.089_bib6","first-page":"64","article-title":"Heart rate as a therapeutic target in heart failure","volume":"1","author":"Kjekshus","year":"1999","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.amjcard.2016.08.089_bib7","doi-asserted-by":"crossref","first-page":"784","DOI":"10.7326\/0003-4819-150-11-200906020-00006","article-title":"Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure","volume":"150","author":"McAlister","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjcard.2016.08.089_bib8","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/eurjhf\/hfs060","article-title":"Heart rate achieved or beta-blocker dose in patients with chronic heart failure: which is the better target?","volume":"14","author":"Cullington","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2016.08.089_bib9","series-title":"l(f) Current Inhibition in Treatment of Angina Pectoris","article-title":"New perspectives for the treatment of stable angina","author":"Borer","year":"2003"},{"key":"10.1016\/j.amjcard.2016.08.089_bib10","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1054\/jcaf.2003.34","article-title":"Tolerability to beta-blocker therapy among heart failure patients in clinical practice","volume":"9","author":"Butler","year":"2003","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.amjcard.2016.08.089_bib11","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0140-6736(10)61259-7","article-title":"Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial","volume":"376","author":"Bohm","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2016.08.089_bib12","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/CIRCULATIONAHA.109.934471","article-title":"Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF)","volume":"122","author":"Fonarow","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2016.08.089_bib13","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0195-668X(02)00823-0","article-title":"The EuroHeart Failure survey programme\u2014a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis","volume":"24","author":"Cleland","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2016.08.089_bib14","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/eurjhf\/hft050","article-title":"EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot)","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2016.08.089_bib15","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijcard.2011.06.098","article-title":"Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial)","volume":"151","author":"Volterrani","year":"2011","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2016.08.089_bib16","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2016.08.089_bib17","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.amjcard.2013.10.033","article-title":"Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study)","volume":"113","author":"Borer","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2016.08.089_bib18","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","article-title":"Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2016.08.089_bib19","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1093\/eurheartj\/ehp358","article-title":"Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial","volume":"30","author":"Fox","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2016.08.089_bib20","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa1406430","article-title":"Ivabradine in stable coronary artery disease without clinical heart failure","volume":"371","author":"Fox","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2016.08.089_bib21","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jama.283.10.1295","article-title":"Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR\/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group","volume":"283","author":"Hjalmarson","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2016.08.089_bib22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00392-012-0467-8","article-title":"Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study","volume":"102","author":"Bohm","year":"2013","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.amjcard.2016.08.089_bib23","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1093\/eurheartj\/ehr311","article-title":"Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy","volume":"32","author":"Tardif","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2016.08.089_bib24","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1093\/eurheartj\/ehr343","article-title":"Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study","volume":"32","author":"Ekman","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2016.08.089_bib25","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/pds.1234","article-title":"The effect of beta-blocker therapy on quality of life in heart failure patients: a systematic review and meta-analysis","volume":"16","author":"Dobre","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.amjcard.2016.08.089_bib26","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/ejhf.347","article-title":"Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial","volume":"17","author":"Komajda","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2016.08.089_bib27","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/eurjhf\/hft102","article-title":"Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study","volume":"15","author":"Tavazzi","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2016.08.089_bib28","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/ejhf.114","article-title":"Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT","volume":"16","author":"Komajda","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2016.08.089_bib29","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ijcard.2013.10.068","article-title":"Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study","volume":"170","author":"Tavazzi","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2016.08.089_bib30","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1093\/eurjhf\/hft072","article-title":"Impact of left bundle branch block on heart rate and its relationship to treatment with ivabradine in chronic heart failure","volume":"15","author":"Reil","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2016.08.089_bib31","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1093\/eurheartj\/ehs259","article-title":"Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study","volume":"33","author":"Borer","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2016.08.089_bib32","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1093\/eurheartj\/ehm489","article-title":"Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials","volume":"28","author":"Cucherat","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2016.08.089_bib33","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ahj.2013.06.024","volume":"166","author":"Fox","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2016.08.089_bib34","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(08)61171-X","article-title":"Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2016.08.089_bib35","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000449243","article-title":"Efficacy profile of ivabradine in patients with heart failure plus angina pectoris","volume":"136","author":"Borer","year":"2016","journal-title":"Cardiology"},{"key":"10.1016\/j.amjcard.2016.08.089_bib36","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/01.CIR.0000048143.25023.87","article-title":"Antianginal and anti-ischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial","volume":"107","author":"Borer","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2016.08.089_bib37","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1167\/iovs.09-3680","article-title":"Effect of HCN channel inhibition on retinal morphology and function in normal and dystrophic rodents","volume":"51","author":"Della Santina","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.amjcard.2016.08.089_bib38","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2165\/00044011-200929050-00006","article-title":"Effect of ivabradine, a novel antianginal agent, on driving performance: a randomized, double-blind, placebo-controlled trial in healthy volunteers","volume":"29","author":"Macher","year":"2009","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.amjcard.2016.08.089_bib39","first-page":"1064","article-title":"Budget impact of adding Corlanor\u00ae (ivabradine) to standard of care in patients with chronic systolic heart failure in the United States","volume":"22","author":"Borer","year":"2016","journal-title":"J\u00a0Manag Care Pharm"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914916315053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914916315053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T03:40:45Z","timestamp":1724470845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914916315053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0002914916315053"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2016.08.089","relation":{},"ISSN":["0002-9149"],"issn-type":[{"type":"print","value":"0002-9149"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benefits of Heart Rate Slowing With Ivabradine in Patients With Systolic Heart Failure and Coronary Artery Disease","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2016.08.089","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}